Athera Biotechnologies AB

May 30, 2011 09:16 ET

Study Mapping Genetic and Environmental Links of Anti-PC Published in Atherosclerosis

SOLNA, SWEDEN--(Marketwire - May 30, 2011) -

Scientists suggest an independent role of anti-PC as a biomarker in cardiovascular disease in a study just published on-line in Atherosclerosis. The testing was performed using Athera Biotechnologies CVDefine® kit.

Previous studies have reported that low levels of anti-PC are linked to development of atherosclerosis and serious cardiovascular consequences like heart attack and stroke. This study measured anti-PC levels in samples from 2036 elderly twins, with an observed heritable component of 40%. This may help to explain the strong genetic impact on cardiovascular risk.

"We are already developing a therapeutic antibody for prevention of secondary cardiovascular events in myocardial infarction patients with low levels of anti- PC. These new findings indicate that the novel biomarker anti-PC can provide information on atherosclerotic progression not already captured by other established biomarkers", says Carina Schmidt, CEO of Athera.

About Athera Biotechnologies AB (publ)

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach.

PC-mAb from Athera is currently in pre-clinical development, using a unique fully human monoclonal antibody. PC-mAb is being developed to restore cardio- protective levels of anti-PC and prevent secondary CVD events after acute coronary syndrome.

In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera's novel therapeutics.

Athera, a Swedish company, is part of the Karolinska Development AB (publ) portfolio.

News Release as PDF:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Athera Biotechnologies AB via Thomson Reuters ONE


Contact Information

  • For further Information:
    Athera Biotechnologies AB (publ)
    Chief Executive Officer
    Carina Schmidt
    Tel +46 761938190
    Email Contact